Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 10, 2024, Adial Pharmaceuticals, Inc. (the "Company") provided Dr. Bankole A. Johnson with notice of the termination of the Company's consulting agreement with Dr. Johnson, entered into as of March 24, 2019, as amended as of March 22, 2022 and September 8, 2022 (the "Consulting Agreement"). The termination is effective May 17, 2024. As a result of the termination of the Consulting Agreement, effective as of May 17, 2024, Dr. Johnson will no longer serve as the Company's Chief Medical Officer.